Skip to main content

Table 2 Baseline Characteristics

From: The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care

Characteristic Usual care before vs. during the trial Usual care pre-trial vs. non-enrolled vs. usual care controls
Pre-trial period
(N = 200)
During-trial period (N = 229) Pre-trial group (N = 200) Non-enrolled group (N = 155) Usual care control group (N = 74)
Age, years (mean [SD]) 74.5 (7.2) 75.2 (6.9) 74.5 (7.2) 75.1 (6.8) 75.4 (7.2)
Males (n - %) 110 (55) 148 (64.6) 110 (55) 101 (65.2) 47 (63.5)
APACHE II score (median [IQR]) 26 (20–31) 26 (21–31) 26 (20–31) 27 (22–31) 25.5 (20–29)
Comorbidities (n [%])
Cardiac
  Supraventricular arrhythmia 48 (24) 66 (28.8) 48 (24) 47 (30.3) 19 (25.7)
  Ventricular arrhythmia 0 (0) 3 (1.3) 0 (0) 3 (1.9) 0 (0)
  Angina, MI, previous PCI, or CABG 51 (25.5) 63 (27.5) 51 (25.5) 55 (35.5) 8 (10.8)
  CHF class I-III 24 (12.1) 42 (18.3) 24 (12.1) 32 (20.7) 10 (13.5)
  CHF class IV 3 (1.5) 5 (2.2) 3 (1.5) 0 (0) 5 (6.8)
Vascular
  Chronic hypertension 126 (63) 153 (66.8) 126 (63) 102 (65.8) 51 (68.9)
  Peripheral vascular disease or claudication 37 (18.5) 29 (12.7) 37 (18.5) 23 (14.8) 6 (8.1)
  Cerebrovascular disease 19 (9.5) 40 (17.5) 19 (9.5) 22 (14.2) 18 (24.3)
Endocrine
  Diabetes 75 (37.5) 87 (38) 75 (37.5) 57 (36.8) 30 (40.5)
Renal
  Chronic dialysis 15 (7.5) 9 (3.9) 15 (7.5) 4 (2.6) 5 (6.8)
Gastrointestinal
  Moderate to severe liver disease 7 (3.5) 9 (3.9) 7 (3.5) 6 (3.9) 3 (4.1)
Respiratory
  Chronic lung disease 54 (27) 66 (28.8) 54 (27) 50 (32.3) 16 (21.6)
Immunosuppression
  Chemotherapy or chronic immunosuppressive 42 (21) 35 (15.3) 42 (21) 28 (18.1) 7 (9.5)
  medications or transplantation      
Neurologic
  Cognitive impairment 16 (8) 16 (7) 16 (8.0) 14 (9) 2(2.7)
Reason for ICU Admission (n [%])
Medical
  Cardiovascular/Vascular 3 (0.7) 10 (2.3) 3 (0.7) 9 (2.1) 1 (0.2)
  Respiratory 38 (8.9) 52 (12.1) 38 (8.9) 40 (9.3) 12 (2.8)
  Gastrointestinal 11 (2.6) 13 (3.0) 11 (2.6) 8 (1.9) 5 (1.2)
  Sepsis 99 (23.1) 101 (23.5) 99 (23.1) 64 (14.9) 37 (8.6)
  Other 8 (1.9) 8 (1.9) 8 (1.9) 3 (0.7) 5 (1.2)
Surgical
  Cardiovascular/vascular 4 (0.9) 3 (0.7) 4 (0.9) 3 (0.7) 0 (0)
  Respiratory 14 (3.3) 6 (1.4) 14 (3.3) 6 (1.4) 0 (0)
  Gastrointestinal 19 (4.4) 30 (7.0) 19 (4.4) 18 (4.2) 12 (2.8)
  Other 4 (0.9) 6 (1.4) 4 (0.9) 4 (0.9) 2 (0.5)
Life support at baseline (n [%])
 Invasive ventilation 102 (51.0) 144 (62.9) 102 (51.0) 95 (61.3) 49 (66.2)
 Non-invasive ventilation 75 (37.5) 50 (21.8) 75 (37.5) 33 (21.3) 17 (23)
 Renal replacement therapy 17 (8.5) 10 (4.4) 17 (8.5) 6 (3.9) 4 (5.4)
MAP at inclusion, mmHg (mean [SD]) 68.2 (13.7) 70 (13.1) 68.2 (13.7) 68.9 (14.4) 72.2 (9.7)
Vasopressor dose-rate at inclusion, ug/kg/min (mean [SD]) 0.15 (0.23) 0.15 (0.18) 0.15 (0.23) 0.13 (0.17) 0.19 (0.19)
  1. Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II score, CABG coronary artery bypass grafting, CHF congestive heart failure, ICU intensive care unit, IQR interquartile range, MAP mean arterial pressure, MI myocardial infarction, PCI percutaneous coronary intervention, SD standard deviation